Following 110 years of neglect, an official day for Chagas disease is declared 24/05/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 24 May 2019 The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease. Image Credits: DNDi. Continue reading -> New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts
Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Posts navigation Older postsNewer posts